Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 2:15 AM
Ignite Modification Date:
2025-12-26 @ 12:44 AM
NCT ID:
NCT00102960
Group ID:
EG000
Title:
ART-Deferred
Description:
For participants with a CD4% of at least 25%, ART deferred until necessary. Once ART therapy was initiated, it was taken continuously.
Zidovudine: First Line Regimen: Given twice daily at a dose of 240 mg/m\^2 of body surface area. Dose was adjusted by age as the children grew older.
Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily
Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m\^2
Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
Didanosine: Second Line Regimen: Either 100 mg/m\^2 or 120 mg/m\^2 taken orally twice daily. Dosage depends on age.
Efavirenz: Second Line Regimen: taken orally once daily. Dosage depends on weight.
Nevirapine: Second Line Regimen: 150 - 200 mg/m\^2 taken orally twice daily.
Deaths Number Affected:
23
Deaths Number At Risk:
None
Serious Number Affected:
79
Serious Number At Risk:
125
Other Number Affected:
123
Other Number At Risk:
125
Study:
NCT00102960
Results Section:
NCT00102960
Adverse Events Module:
NCT00102960